The Krebs cycle—also known as the citric acid cycle—is widely recognized as the metabolic engine of our cells. Deep in the heart of mitochondria, this pathway converts energetic molecules into usable fuel (ATP), keeping cells alive. However, recent studies are unveiling a much more profound role for this cycle: its direct influence on cellular aging and the development of cancer. In particular, the metabolite α-ketoglutarate (AKG), one of the cycle’s key intermediates, has emerged as a master regulator of cellular senescence, genomic stability, and the ability of cells to preserve their functionality over time.

Cellular senescence is a state in which cells permanently lose their ability to divide—but do not die. Although it was initially viewed as a protective barrier against cancer, preventing damaged cells from proliferating uncontrollably, we now understand that persistent senescence has harmful consequences. Senescent cells secrete a variety of inflammatory molecules, proteases, and growth factors that disrupt the surrounding tissue microenvironment. This phenomenon, known as the SASP (senescence-associated secretory phenotype), contributes not only to systemic aging but also promotes tumor initiation and progression by stimulating angiogenesis, cellular migration, and immune evasion. Thus, finding ways to delay, reverse, or eliminate senescence has become a top priority in anti-aging and cancer medicine.

In this context, a recent study published in Trends in Endocrinology & Metabolism focuses on the central role of AKG as a modulator of senescence. The researchers observed that in human mesenchymal stem cells (MSCs), AKG levels significantly decline as cells age. This reduction is accompanied by the upregulation of classic senescence markers such as p16^INK4a^, p21^CIP1^, IL-6, and γH2AX (a marker of DNA damage). When the cells were supplemented with exogenous AKG in the form of DM-AKG (a more stable and bioavailable version), these changes were reversed: cells regained proliferative capacity, DNA damage was reduced, and youthful characteristics were restored.

But how exactly does AKG achieve this rejuvenating effect? The study uncovered a fascinating mechanism: AKG enhances the interaction between the regulatory protein OGFOD1 (an AKG-dependent dioxygenase) and the essential ribosomal protein RPS23. RPS23 plays a critical role in ensuring translational fidelity—particularly in accurately recognizing stop codons on messenger RNA, thus preventing the synthesis of aberrant proteins. Loss of this control leads to protein errors, cellular stress, and ultimately senescence. Strikingly, this regulatory pathway requires both iron and AKG as cofactors: without AKG, OGFOD cannot properly modify RPS23, compromising the core machinery of protein synthesis.

This link between metabolism, protein translation, and aging has far-reaching implications in oncology. In many tumors, the ribosomal machinery is altered, generating a high burden of misfolded proteins, activating endoplasmic reticulum stress pathways, and promoting genomic instability. By restoring translational precision, AKG may act indirectly as a tumor suppressor—reinforcing the fidelity of the cell’s core systems and preventing the accumulation of errors that predispose cells to malignant transformation. Moreover, by reducing SASP factors and preserving genome integrity, AKG could prevent the tumor microenvironment from becoming more permissive to cancer progression.

Another key mechanism is AKG’s role in epigenetic regulation. It serves as a vital cofactor for TET (Ten-Eleven Translocation) enzymes and JmjC domain-containing histone demethylases—both involved in removing repressive epigenetic marks from DNA and histones. When AKG levels drop, these enzymes cannot function properly, resulting in widespread transcriptional dysregulation that promotes both senescence and tumorigenesis. It is particularly noteworthy that mutations in IDH1 (the enzyme that converts isocitrate to AKG) are common in gliomas and leukemias. These mutations generate an oncometabolite, 2-hydroxyglutarate, which structurally mimics AKG but inhibits the same epigenetic enzymes, blocking cellular differentiation and driving malignant progression.

Figure 1. Low α-ketoglutarate (AKG) levels lead to impaired translation, DNA damage, and SASP secretion. Boosting AKG through DM-AKG, IDH1 activation, or the natural compound scutellarin enables OGFOD1 to activate RPS23, restoring protein synthesis accuracy and reducing senescence-associated markers.

The study also explored pharmacological strategies to increase endogenous AKG levels. In particular, the researchers tested a natural flavonoid called scutellarin, which activates IDH1. In both cell cultures and aged mice, scutellarin raised AKG levels, reduced cellular senescence, restored proliferation, and improved physiological markers of aging—including memory, skin thickness, bone quality, and the expression of youth-associated genes. This finding is crucial, as it shows we can not only supplement AKG but also safely and naturally stimulate its internal production.

From a therapeutic perspective, these observations open a new chapter in precision medicine. AKG could be incorporated into combination strategies to combat aging and prevent cancer progression—especially in patients undergoing chemotherapy or radiotherapy, where treatment-induced senescence (TIS) contributes to relapse and metastasis. Furthermore, combining AKG with senolytics (drugs that selectively eliminate senescent cells) or SASP inhibitors may generate powerful synergistic effects.

In conclusion, this study redefines our understanding of cellular metabolism. AKG is not merely a metabolite of the Krebs cycle—it is an epigenetic, translational, and anti-senescent regulator with direct impact on cancer prevention. Its influence on ribosomal machinery, chromatin regulation, and the tumor microenvironment make it a high-potential therapeutic target. At a time when aging is recognized as the primary risk factor for most chronic diseases—including cancer—intervening on metabolic hubs like AKG could provide a new, more physiological, less toxic, and profoundly effective approach to therapy.

Main Reference:

Gyanwali, B., Lim, Z. X., Soh, J., Lim, C., Guan, S. P., Goh, J., Maier, A. B., & Kennedy, B. K. (2022). Alpha-Ketoglutarate dietary supplementation to improve health in humans. Trends in endocrinology and metabolism: TEM, 33(2), 136–146. https://doi.org/10.1016/j.tem.2021.11.003

Other References:

Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., Franceschi, C., Lithgow, G. J., Morimoto, R. I., Pessin, J. E., Rando, T. A., Richardson, A., Schadt, E. E., Wyss-Coray, T., & Sierra, F. (2014). Geroscience: linking aging to chronic disease. Cell, 159(4), 709–713. https://doi.org/10.1016/j.cell.2014.10.039

López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194–1217. https://doi.org/10.1016/j.cell.2013.05.039

Barardo, D., Thornton, D., Thoppil, H., Walsh, M., Sharifi, S., Ferreira, S., Anžič, A., Fernandes, M., Monteiro, P., Grum, T., Cordeiro, R., De-Souza, E. A., Budovsky, A., Araujo, N., Gruber, J., Petrascheck, M., Fraifeld, V. E., Zhavoronkov, A., Moskalev, A., & de Magalhães, J. P. (2017). The DrugAge database of aging-related drugs. Aging cell, 16(3), 594–597. https://doi.org/10.1111/acel.12585